Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board, with total revenue of $28.6M significantly exceeding the $17.5M expectation due to a strong $25.3M net product revenue from the MYQORZO launch. GAAP EPS of -$1.50 was narrower than the -$1.64 mean estimate, aided by controlled operating losses. Management raised FY26 expense guidance to $860M-$890M to support commercial readiness for the non-obstructive HCM indication, reflecting confidence in the pipeline after positive Phase 3 ACACIA-HCM data.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cytokinetics(CYTK) the Revenue is 28.62 M (-57.13%), Beat estimate;the EBIT is -179.17 M (-60.68%), Beat estimate;the EPS is -1.5 (-33.93%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B57.13%
0.02B73.85%
+0.01B16.72%
EBITExceed expectations
-0.18B60.68%
-0.19B73.79%
+0.01B13.11%
EPSExceed expectations
-1.533.93%
-1.638646.30%
+0.138612.37%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf